Global Diabetic Nephropathy Market By Diabetics Type (Type 1, Type 2) By Diagnosis (Urinary albumin test, Albumin/creatinine ratio, Imaging tests, Kidney biopsy, Others) By Treatment (Drug Treatment (SGLT2 inhibitors, Angiotensin converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs), Others) Dietary Changes, Dialysis, Kidney Transplant); By End User(Hospitals And Clinics, Diabetes Management Centers, Research Institutes); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Deterioration of kidney function is referred to as nephropathy. Kidney failure, end-stage renal disease, and other terms for the latter stage of nephropathy. The diabetes complication of hypertension, or high blood pressure, is considered to produce diabetic nephropathy most directly. Both the disease's damage and its underlying cause, diabetic nephropathy, are thought to cause hypertension. Increasing blood pressure is frequently a side effect of renal disease as it advances. The body's fluid and salt balance is maintained by the kidneys, which is essential for lowering blood pressure and safeguarding cardiovascular health. Diabetes, whether type 1, type 2, or gestational diabetes, occurs when the body is unable to use or make insulin as it should. The beginning of diabetic nephropathy is gradual. According to a study found that 15 years after a diabetes diagnosis, a third of patients had high levels of albumin in their urine and less than half of these individuals experience complete nephropathy. The rising R&D investments on drug research and the rising prevalence of diabetes are predicted to drive the global market for diabetic nephropathy. For instance, the International Diabetes Federation estimates that 642 million people would have diabetes by 2040, up from the current 415 million cases worldwide. Thus with rising cases of people suffering from diabetes will boost the diabetic nephropathy market growth.
It is discovered during the COVID-19 pandemic that diabetic nephropathy is one of the independent risk variables that forecasts a poor outcome following SARS-CoV2 infection. The study found that the COVID-19-related fatality rate for diabetic nephropathy and the combination of type 2 diabetes and obesity was higher than 70% over that for all other risk factors. When compared to patients with chronic kidney disease alone, patients with diabetic nephropathy had approximately two times the rates of COVID-19 pneumonia, greater rates of intubation, and higher probabilities of admission and mortality once hospitalised. Various clinical trials for diabetic nephropathy are been carried out for treatment which has led to the growth of the market.
In terms of revenue, global diabetic nephropathy market was valued at US$ 2.49 Bn in 2021 growing at a CAGR of 5.2% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Diabetic Nephropathy Market Revenue & Forecast, (US$ Million), 2015 – 2030
Diabetics Type Outlook
Based on diabetes type outlook, the market is segmented into type 1 diabetics and type 2 diabetics. Nephropathy will develop in over one-third of all type 2 diabetic patients. Despite the existence of treatments that have been shown to halt its progression, diabetic nephropathy is linked to a death rate of 36% over a five-year period. It is estimated that 20% to 40% of those with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes suffer from the syndrome known as diabetic nephropathy. About one-third of individuals in western countries who require chronic renal replacement treatment have diabetes, the majority type 2. Furthermore type 2 diabetes incidence is still rising and the mortality rate from cardiovascular reasons is steadily dropping, the number of type 2 diabetics with end-stage renal disease (ESRD) is really rising quickly. Thus with various rising number of cases of diabetes amongst a huge population the global diabetic nephropathy market is expected to flourish in the upcoming years.
Treatment Outlook
Based on treatment, the global diabetic nephropathy market is segmented into drugs treatment, dietary changes, dialysis, kidney transplant. Monitoring and controlling blood pressure and blood glucose levels is the major goal of treatment. The usage of drugs could be involved in this. Various drugs such as SGLT2 inhibitors, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and others are used to control blood pressure, protect the kidney function and prevent the further damage. Moreover managing diet is also one amongst the crucial treatments for early stages of diabetic nephropathy, wherein managing blood sugar levels along with the sodium which can raise blood pressure. Furthermore dialysis or a kidney transplant will be required if diabetic nephropathy develops into ESRD. For the rest of their lives or until a kidney transplant is possible, they will typically require dialysis. Furthermore advancements and FDA approved drugs are likely to boost the global diabetic nephropathy market in the upcoming years.
Region Outlook
Based on the regions, North America had the highest share in the diabetic nephropathy market in the year 2021. Although obesity is frequently cited as the primary cause of the rising incidence of diabetes in North America, other variables, including age, ethnicity, lifestyle (particularly physical inactivity and a diet high in calories), socioeconomic status, education, and urbanisation, have also been identified as potentially significant variables. In the year 2021, 28.7 million people, including 28.5 million adults were diagnosed with diabetes. In the last few years there has been rising awareness amongst a huge population about the diabetic nephropathy in United States and Canada. Moreover the leading players in the market are focused on introducing various advanced treatments and drugs for diabetic nephropathy treatments. Additionally healthcare organizations along with government assistance are investing into nephrology and its testing facilities which is supporting the growth of diabetic nephropathy market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global diabetic nephropathy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the diabetic nephropathy market are mentioned below:
- AbbVie Inc.
- AstraZeneca
- Bayer AG
- ChemoCentryx, Inc.
- Genkyotex
- Goldfinch Bio, Inc.
- Janssen Pharmaceutical Companies (Johnson & Johnson.)
- Mesoblast Ltd
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Other Industry Participants
Global Diabetic Nephropathy Market:
By Diabetics Type
- Type 1
- Type 2
By Diagnosis
- Urinary albumin test.
- Albumin/creatinine ratio
- Imaging tests
- Kidney biopsy
- Others
By Treatment
- Drug Treatment
- SGLT2 inhibitors
- Angiotensin converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Others
- Dietary Changes
- Dialysis
- Kidney Transplant
By End Users
- Hospitals And Clinics
- Diabetes Management Centers
- Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
Rest of Latin America
Table of Contents
Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Diabetic Nephropathy Market
6.
Market
Synopsis: Diabetic Nephropathy Market
7.
Diabetic
Nephropathy Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Diabetic Nephropathy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Diabetic Nephropathy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Diabetic
Nephropathy Market
8.
Global
Diabetic Nephropathy Market Analysis and
Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Diabetic Nephropathy Market Revenue (US$ Mn)
8.2. Global Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
8.2.1. Type 1
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Type 2
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Diabetics Type
9.
Global
Diabetic Nephropathy Market Analysis and
Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
9.2.1. Urinary albumin test
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Albumin/creatinine ratio
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Imaging tests
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Kidney biopsy.
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 – 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Others
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 – 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Diagnosis
10. Global Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
10.2.1. Drug Treatment (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022
– 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on SGLT2 inhibitors, Angiotensin converting enzyme (ACE)
inhibitors, Angiotensin receptor blockers (ARBs), Others )
10.2.1.1.
SGLT2
inhibitors
10.2.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
10.2.1.3.
Angiotensin
receptor blockers (ARBs)
10.2.1.4.
Others
10.2.2. Dietary Changes
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 – 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Dialysis
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 – 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Kidney Transplant
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.4.3.
Market
Forecast, 2022 – 2030
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1.
North
America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2.
Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3.
Asia
Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4.
Middle
East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5.
Latin
America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Treatment
11. Global Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By End
Users
11.2.1. Hospitals And Clinics
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Diabetes Management Centers
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 – 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Research Institutes
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 – 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North America Diabetic Nephropathy Market Revenue (US$ Mn)
12.2. North America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
12.2.1. Type 1
12.2.2. Type 2
12.3. North America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.3.1. Urinary albumin test
12.3.2. Albumin/creatinine ratio
12.3.3. Imaging tests
12.3.4. Kidney biopsy.
12.3.5. Others
12.4. North America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
12.4.1. Drug Treatment
12.4.1.1.
SGLT2
inhibitors
12.4.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
12.4.1.3.
Angiotensin
receptor blockers (ARBs)
12.4.1.4.
Others
12.4.2. Dietary Changes
12.4.3. Dialysis
12.4.4. Kidney Transplant
12.5. North America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.1. Hospitals And Clinics
12.5.2. Diabetes Management Centers
12.5.3. Research Institutes
12.6. North America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1.
U.S
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
12.6.1.1.1.
Type 1
12.6.1.1.2.
Type 2
12.6.1.2.
U.S
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
12.6.1.2.1.
Urinary
albumin test
12.6.1.2.2.
Albumin/creatinine
ratio
12.6.1.2.3.
Imaging
tests
12.6.1.2.4.
Kidney
biopsy.
12.6.1.2.5.
Others
12.6.1.3.
U.S
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
12.6.1.3.1.
Drug Treatment
12.6.1.3.1.1. SGLT2 inhibitors
12.6.1.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
12.6.1.3.1.3. Angiotensin receptor blockers (ARBs)
12.6.1.3.1.4. Others
12.6.1.3.2.
Dietary
Changes
12.6.1.3.3.
Dialysis
12.6.1.3.4.
Kidney
Transplant
12.6.1.4.
U.S
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.1.4.1.
Hospitals
And Clinics
12.6.1.4.2.
Diabetes
Management Centers
12.6.1.4.3.
Research
Institutes
12.6.2. Canada
12.6.2.1.
Canada
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
12.6.2.1.1.
Type 1
12.6.2.1.2.
Type 2
12.6.2.2.
Canada
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
12.6.2.2.1.
Urinary albumin
test
12.6.2.2.2.
Albumin/creatinine
ratio
12.6.2.2.3.
Imaging
tests
12.6.2.2.4.
Kidney
biopsy.
12.6.2.2.5.
Others
12.6.2.3.
Canada
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
12.6.2.3.1.
Drug
Treatment
12.6.2.3.1.1. SGLT2 inhibitors
12.6.2.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
12.6.2.3.1.3. Angiotensin receptor blockers (ARBs)
12.6.2.3.1.4. Others
12.6.2.3.2.
Dietary
Changes
12.6.2.3.3.
Dialysis
12.6.2.3.4.
Kidney
Transplant
12.6.2.4.
Canada
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.2.4.1.
Hospitals
And Clinics
12.6.2.4.2.
Diabetes
Management Centers
12.6.2.4.3.
Research
Institutes
12.6.3. Mexico
12.6.3.1.
Mexico
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
12.6.3.1.1.
Type 1
12.6.3.1.2.
Type 2
12.6.3.2.
Mexico
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
12.6.3.2.1.
Urinary
albumin test
12.6.3.2.2.
Albumin/creatinine
ratio
12.6.3.2.3.
Imaging
tests
12.6.3.2.4.
Kidney
biopsy.
12.6.3.2.5.
Others
12.6.3.3.
Mexico
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
12.6.3.3.1.
Drug
Treatment
12.6.3.3.1.1. SGLT2 inhibitors
12.6.3.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
12.6.3.3.1.3. Angiotensin receptor blockers (ARBs)
12.6.3.3.1.4. Others
12.6.3.3.2.
Dietary
Changes
12.6.3.3.3.
Dialysis
12.6.3.3.4.
Kidney
Transplant
12.6.3.4.
Mexico
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.3.4.1.
Hospitals
And Clinics
12.6.3.4.2.
Diabetes
Management Centers
12.6.3.4.3.
Research
Institutes
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Diabetics Type
12.6.4.1.1.
Type 1
12.6.4.1.2.
Type 2
12.6.4.2.
Rest of
North America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.6.4.2.1.
Urinary
albumin test
12.6.4.2.2.
Albumin/creatinine
ratio
12.6.4.2.3.
Imaging
tests
12.6.4.2.4.
Kidney
biopsy.
12.6.4.2.5.
Others
12.6.4.3.
Rest of
North America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.6.4.3.1.
Drug
Treatment
12.6.4.3.1.1. SGLT2 inhibitors
12.6.4.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
12.6.4.3.1.3. Angiotensin receptor blockers (ARBs)
12.6.4.3.1.4. Others
12.6.4.3.2.
Dietary
Changes
12.6.4.3.3.
Dialysis
12.6.4.3.4.
Kidney
Transplant
12.6.4.4.
Rest of
North America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1.
Hospitals
And Clinics
12.6.4.4.2.
Diabetes
Management Centers
12.6.4.4.3.
Research
Institutes
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Diabetics Type
12.7.3. By Diagnosis
12.7.4. By Treatment
12.7.5. By End Users
13. Europe Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe Diabetic Nephropathy Market Revenue (US$ Mn)
13.2. Europe Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
13.2.1. Type 1
13.2.2. Type 2
13.3. Europe Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.3.1. Urinary albumin test
13.3.2. Albumin/creatinine ratio
13.3.3. Imaging tests
13.3.4. Kidney biopsy.
13.3.5. Others
13.4. Europe Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
13.4.1. Drug Treatment
13.4.1.1.
SGLT2 inhibitors
13.4.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
13.4.1.3.
Angiotensin
receptor blockers (ARBs)
13.4.1.4.
Others
13.4.2. Dietary Changes
13.4.3. Dialysis
13.4.4. Kidney Transplant
13.5. Europe Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.1. Hospitals And Clinics
13.5.2. Diabetes Management Centers
13.5.3. Research Institutes
13.6. Europe Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. France
13.6.1.1.
France
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
13.6.1.1.1.
Type 1
13.6.1.1.2.
Type 2
13.6.1.2.
France
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
13.6.1.2.1.
Urinary
albumin test
13.6.1.2.2.
Albumin/creatinine
ratio
13.6.1.2.3.
Imaging
tests
13.6.1.2.4.
Kidney
biopsy.
13.6.1.2.5.
Others
13.6.1.3.
France
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.1.3.1.
Drug
Treatment
13.6.1.3.1.1. SGLT2 inhibitors
13.6.1.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.1.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.1.3.1.4. Others
13.6.1.3.2.
Dietary
Changes
13.6.1.3.3.
Dialysis
13.6.1.3.4.
Kidney
Transplant
13.6.1.4.
France
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.1.4.1.
Hospitals
And Clinics
13.6.1.4.2.
Diabetes
Management Centers
13.6.1.4.3.
Research
Institutes
13.6.2. The UK
13.6.2.1.
The UK
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
13.6.2.1.1.
Type 1
13.6.2.1.2.
Type 2
13.6.2.2.
The UK
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
13.6.2.2.1.
Urinary
albumin test
13.6.2.2.2.
Albumin/creatinine
ratio
13.6.2.2.3.
Imaging
tests
13.6.2.2.4.
Kidney
biopsy.
13.6.2.2.5.
Others
13.6.2.3.
The UK
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.2.3.1.
Drug
Treatment
13.6.2.3.1.1. SGLT2 inhibitors
13.6.2.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.2.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.2.3.1.4. Others
13.6.2.3.2.
Dietary
Changes
13.6.2.3.3.
Dialysis
13.6.2.3.4.
Kidney
Transplant
13.6.2.4.
The UK
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.2.4.1.
Hospitals
And Clinics
13.6.2.4.2.
Diabetes
Management Centers
13.6.2.4.3.
Research
Institutes
13.6.3. Spain
13.6.3.1.
Spain
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
13.6.3.1.1.
Type 1
13.6.3.1.2.
Type 2
13.6.3.2.
Spain
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
13.6.3.2.1.
Urinary
albumin test
13.6.3.2.2.
Albumin/creatinine
ratio
13.6.3.2.3.
Imaging
tests
13.6.3.2.4.
Kidney
biopsy.
13.6.3.2.5.
Others
13.6.3.3.
Spain
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.3.3.1.
Drug
Treatment
13.6.3.3.1.1. SGLT2 inhibitors
13.6.3.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.3.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.3.3.1.4. Others
13.6.3.3.2.
Dietary
Changes
13.6.3.3.3.
Dialysis
13.6.3.3.4.
Kidney
Transplant
13.6.3.4.
Spain
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.3.4.1.
Hospitals
And Clinics
13.6.3.4.2.
Diabetes
Management Centers
13.6.3.4.3.
Research
Institutes
13.6.4. Germany
13.6.4.1.
Germany
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
13.6.4.1.1.
Type 1
13.6.4.1.2.
Type 2
13.6.4.2.
Germany
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
13.6.4.2.1.
Urinary
albumin test
13.6.4.2.2.
Albumin/creatinine
ratio
13.6.4.2.3.
Imaging
tests
13.6.4.2.4.
Kidney
biopsy.
13.6.4.2.5.
Others
13.6.4.3.
Germany
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.4.3.1.
Drug
Treatment
13.6.4.3.1.1. SGLT2 inhibitors
13.6.4.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.4.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.4.3.1.4. Others
13.6.4.3.2.
Dietary
Changes
13.6.4.3.3.
Dialysis
13.6.4.3.4.
Kidney
Transplant
13.6.4.4.
Germany
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.4.4.1.
Hospitals
And Clinics
13.6.4.4.2.
Diabetes
Management Centers
13.6.4.4.3.
Research
Institutes
13.6.5. Italy
13.6.5.1.
Italy
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
13.6.5.1.1.
Type 1
13.6.5.1.2.
Type 2
13.6.5.2.
Italy
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
13.6.5.2.1.
Urinary albumin
test
13.6.5.2.2.
Albumin/creatinine
ratio
13.6.5.2.3.
Imaging
tests
13.6.5.2.4.
Kidney
biopsy.
13.6.5.2.5.
Others
13.6.5.3.
Italy
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.5.3.1.
Drug
Treatment
13.6.5.3.1.1. SGLT2 inhibitors
13.6.5.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.5.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.5.3.1.4. Others
13.6.5.3.2.
Dietary
Changes
13.6.5.3.3.
Dialysis
13.6.5.3.4.
Kidney
Transplant
13.6.5.4.
Italy
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.5.4.1.
Hospitals
And Clinics
13.6.5.4.2.
Diabetes
Management Centers
13.6.5.4.3.
Research
Institutes
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
13.6.6.1.1.
Type 1
13.6.6.1.2.
Type 2
13.6.6.2.
Nordic
Countries Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.6.2.1.
Urinary
albumin test
13.6.6.2.2.
Albumin/creatinine
ratio
13.6.6.2.3.
Imaging
tests
13.6.6.2.4.
Kidney
biopsy.
13.6.6.2.5.
Others
13.6.6.3.
Nordic
Countries Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.6.6.3.1.
Drug
Treatment
13.6.6.3.1.1. SGLT2 inhibitors
13.6.6.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.6.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.6.3.1.4. Others
13.6.6.3.2.
Dietary
Changes
13.6.6.3.3.
Dialysis
13.6.6.3.4.
Kidney
Transplant
13.6.6.4.
Nordic
Countries Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1.
Hospitals
And Clinics
13.6.6.4.2.
Diabetes
Management Centers
13.6.6.4.3.
Research
Institutes
13.6.6.5.
Nordic
Countries Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
13.6.7.1.1.
Type 1
13.6.7.1.2.
Type 2
13.6.7.2.
Benelux
Union Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.7.2.1.
Urinary
albumin test
13.6.7.2.2.
Albumin/creatinine
ratio
13.6.7.2.3.
Imaging
tests
13.6.7.2.4.
Kidney
biopsy.
13.6.7.2.5.
Others
13.6.7.3.
Benelux
Union Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.6.7.3.1.
Drug
Treatment
13.6.7.3.1.1. SGLT2 inhibitors
13.6.7.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.7.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.7.3.1.4. Others
13.6.7.3.2.
Dietary
Changes
13.6.7.3.3.
Dialysis
13.6.7.3.4.
Kidney
Transplant
13.6.7.4.
Benelux
Union Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1.
Hospitals
And Clinics
13.6.7.4.2.
Diabetes
Management Centers
13.6.7.4.3.
Research
Institutes
13.6.7.5.
Benelux
Union Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
13.6.8.1.1.
Type 1
13.6.8.1.2.
Type 2
13.6.8.2.
Rest of
Europe Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
13.6.8.2.1.
Urinary
albumin test
13.6.8.2.2.
Albumin/creatinine
ratio
13.6.8.2.3.
Imaging tests
13.6.8.2.4.
Kidney
biopsy.
13.6.8.2.5.
Others
13.6.8.3.
Rest of
Europe Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.6.8.3.1.
Drug
Treatment
13.6.8.3.1.1. SGLT2 inhibitors
13.6.8.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
13.6.8.3.1.3. Angiotensin receptor blockers (ARBs)
13.6.8.3.1.4. Others
13.6.8.3.2.
Dietary
Changes
13.6.8.3.3.
Dialysis
13.6.8.3.4.
Kidney
Transplant
13.6.8.4.
Rest of
Europe Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1.
Hospitals
And Clinics
13.6.8.4.2.
Diabetes
Management Centers
13.6.8.4.3.
Research
Institutes
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Diabetics Type
13.7.3. By Diagnosis
13.7.4. By Treatment
13.7.5. By End Users
14. Asia Pacific Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn)
14.2. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
14.2.1. Type 1
14.2.2. Type 2
14.3. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.3.1. Urinary albumin test
14.3.2. Albumin/creatinine ratio
14.3.3. Imaging tests
14.3.4. Kidney biopsy.
14.3.5. Others
14.4. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.4.1. Drug Treatment
14.4.1.1.
SGLT2
inhibitors
14.4.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
14.4.1.3.
Angiotensin
receptor blockers (ARBs)
14.4.1.4.
Others
14.4.2. Dietary Changes
14.4.3. Dialysis
14.4.4. Kidney Transplant
14.5. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.1. Hospitals And Clinics
14.5.2. Diabetes Management Centers
14.5.3. Research Institutes
14.6. Asia Pacific Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1.
China
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
14.6.1.1.1.
Type 1
14.6.1.1.2.
Type 2
14.6.1.2.
China
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.6.1.2.1.
Urinary
albumin test
14.6.1.2.2.
Albumin/creatinine
ratio
14.6.1.2.3.
Imaging
tests
14.6.1.2.4.
Kidney
biopsy.
14.6.1.2.5.
Others
14.6.1.3.
China
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
14.6.1.3.1.
Drug
Treatment
14.6.1.3.1.1. SGLT2 inhibitors
14.6.1.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.1.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.1.3.1.4. Others
14.6.1.3.2.
Dietary
Changes
14.6.1.3.3.
Dialysis
14.6.1.3.4.
Kidney
Transplant
14.6.1.4.
China
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.1.4.1.
Hospitals
And Clinics
14.6.1.4.2.
Diabetes
Management Centers
14.6.1.4.3.
Research
Institutes
14.6.2. Japan
14.6.2.1.
Japan
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
14.6.2.1.1.
Type 1
14.6.2.1.2.
Type 2
14.6.2.2.
Japan
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.6.2.2.1.
Urinary
albumin test
14.6.2.2.2.
Albumin/creatinine
ratio
14.6.2.2.3.
Imaging
tests
14.6.2.2.4.
Kidney
biopsy.
14.6.2.2.5.
Others
14.6.2.3.
Japan
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
14.6.2.3.1.
Drug
Treatment
14.6.2.3.1.1. SGLT2 inhibitors
14.6.2.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.2.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.2.3.1.4. Others
14.6.2.3.2.
Dietary
Changes
14.6.2.3.3.
Dialysis
14.6.2.3.4.
Kidney
Transplant
14.6.2.4.
Japan
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.2.4.1.
Hospitals
And Clinics
14.6.2.4.2.
Diabetes
Management Centers
14.6.2.4.3.
Research
Institutes
14.6.3. India
14.6.3.1.
India
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
14.6.3.1.1.
Type 1
14.6.3.1.2.
Type 2
14.6.3.2.
India
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.6.3.2.1.
Urinary
albumin test
14.6.3.2.2.
Albumin/creatinine
ratio
14.6.3.2.3.
Imaging
tests
14.6.3.2.4.
Kidney
biopsy.
14.6.3.2.5.
Others
14.6.3.3.
India
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
14.6.3.3.1.
Drug
Treatment
14.6.3.3.1.1. SGLT2 inhibitors
14.6.3.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.3.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.3.3.1.4. Others
14.6.3.3.2.
Dietary
Changes
14.6.3.3.3.
Dialysis
14.6.3.3.4.
Kidney
Transplant
14.6.3.4.
India
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.3.4.1.
Hospitals
And Clinics
14.6.3.4.2.
Diabetes
Management Centers
14.6.3.4.3.
Research
Institutes
14.6.4. New Zealand
14.6.4.1.
New
Zealand Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
14.6.4.1.1.
Type 1
14.6.4.1.2.
Type 2
14.6.4.2.
New
Zealand Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.4.2.1.
Urinary
albumin test
14.6.4.2.2.
Albumin/creatinine
ratio
14.6.4.2.3.
Imaging
tests
14.6.4.2.4.
Kidney
biopsy.
14.6.4.2.5.
Others
14.6.4.3.
New
Zealand Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.6.4.3.1.
Drug
Treatment
14.6.4.3.1.1. SGLT2 inhibitors
14.6.4.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.4.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.4.3.1.4. Others
14.6.4.3.2.
Dietary
Changes
14.6.4.3.3.
Dialysis
14.6.4.3.4.
Kidney
Transplant
14.6.4.4.
New
Zealand Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1.
Hospitals
And Clinics
14.6.4.4.2.
Diabetes
Management Centers
14.6.4.4.3.
Research
Institutes
14.6.5. Australia
14.6.5.1.
Australia
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
14.6.5.1.1.
Type 1
14.6.5.1.2.
Type 2
14.6.5.2.
Australia
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.6.5.2.1.
Urinary
albumin test
14.6.5.2.2.
Albumin/creatinine
ratio
14.6.5.2.3.
Imaging
tests
14.6.5.2.4.
Kidney
biopsy.
14.6.5.2.5.
Others
14.6.5.3.
Australia
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
14.6.5.3.1.
Drug
Treatment
14.6.5.3.1.1. SGLT2 inhibitors
14.6.5.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.5.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.5.3.1.4. Others
14.6.5.3.2.
Dietary
Changes
14.6.5.3.3.
Dialysis
14.6.5.3.4.
Kidney
Transplant
14.6.5.4.
Australia
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.5.4.1.
Hospitals
And Clinics
14.6.5.4.2.
Diabetes
Management Centers
14.6.5.4.3.
Research
Institutes
14.6.6. South Korea
14.6.6.1.
South
Korea Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
14.6.6.1.1.
Type 1
14.6.6.1.2.
Type 2
14.6.6.2.
South
Korea Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.6.2.1.
Urinary
albumin test
14.6.6.2.2.
Albumin/creatinine
ratio
14.6.6.2.3.
Imaging
tests
14.6.6.2.4.
Kidney
biopsy.
14.6.6.2.5.
Others
14.6.6.3.
South
Korea Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.6.6.3.1.
Drug
Treatment
14.6.6.3.1.1. SGLT2 inhibitors
14.6.6.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.6.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.6.3.1.4. Others
14.6.6.3.2.
Dietary
Changes
14.6.6.3.3.
Dialysis
14.6.6.3.4.
Kidney
Transplant
14.6.6.4.
South
Korea Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1.
Hospitals
And Clinics
14.6.6.4.2.
Diabetes
Management Centers
14.6.6.4.3.
Research
Institutes
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Diabetic Nephropathy Market Revenue
(US$ Mn) and Forecasts, By Diabetics Type
14.6.7.1.1.
Type 1
14.6.7.1.2.
Type 2
14.6.7.2.
Southeast
Asia Diabetic Nephropathy Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
14.6.7.2.1.
Urinary
albumin test
14.6.7.2.2.
Albumin/creatinine
ratio
14.6.7.2.3.
Imaging
tests
14.6.7.2.4.
Kidney
biopsy.
14.6.7.2.5.
Others
14.6.7.3.
Southeast
Asia Diabetic Nephropathy Market Revenue
(US$ Mn) and Forecasts, By Treatment
14.6.7.3.1.
Drug
Treatment
14.6.7.3.1.1. SGLT2 inhibitors
14.6.7.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.7.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.7.3.1.4. Others
14.6.7.3.2.
Dietary
Changes
14.6.7.3.3.
Dialysis
14.6.7.3.4.
Kidney
Transplant
14.6.7.4.
Southeast
Asia Diabetic Nephropathy Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.7.4.1.
Hospitals
And Clinics
14.6.7.4.2.
Diabetes
Management Centers
14.6.7.4.3.
Research
Institutes
14.6.7.5.
Southeast
Asia Diabetic Nephropathy Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
14.6.8.1.1.
Type 1
14.6.8.1.2.
Type 2
14.6.8.2.
Rest of
Asia Pacific Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.6.8.2.1.
Urinary
albumin test
14.6.8.2.2.
Albumin/creatinine
ratio
14.6.8.2.3.
Imaging
tests
14.6.8.2.4.
Kidney
biopsy.
14.6.8.2.5.
Others
14.6.8.3.
Rest of
Asia Pacific Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
14.6.8.3.1.
Drug
Treatment
14.6.8.3.1.1. SGLT2 inhibitors
14.6.8.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
14.6.8.3.1.3. Angiotensin receptor blockers (ARBs)
14.6.8.3.1.4. Others
14.6.8.3.2.
Dietary
Changes
14.6.8.3.3.
Dialysis
14.6.8.3.4.
Kidney
Transplant
14.6.8.4.
Rest of
Asia Pacific Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1.
Hospitals
And Clinics
14.6.8.4.2.
Diabetes
Management Centers
14.6.8.4.3.
Research
Institutes
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Diabetics Type
14.7.3. By Diagnosis
14.7.4. By Treatment
14.7.5. By End Users
15. Middle East and Africa Diabetic
Nephropathy Market Analysis and
Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn)
15.2. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By Diabetics Type
15.2.1. Type 1
15.2.2. Type 2
15.3. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.3.1. Urinary albumin test
15.3.2. Albumin/creatinine ratio
15.3.3. Imaging tests
15.3.4. Kidney biopsy.
15.3.5. Others
15.4. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.4.1. Drug Treatment
15.4.1.1.
SGLT2
inhibitors
15.4.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
15.4.1.3.
Angiotensin
receptor blockers (ARBs)
15.4.1.4.
Others
15.4.2. Dietary Changes
15.4.3. Dialysis
15.4.4. Kidney Transplant
15.5. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1. Hospitals And Clinics
15.5.2. Diabetes Management Centers
15.5.3. Research Institutes
15.6. Middle East and Africa Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
15.6.1.1.1.
Type 1
15.6.1.1.2.
Type 2
15.6.1.2.
Saudi
Arabia Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.1.2.1.
Urinary
albumin test
15.6.1.2.2.
Albumin/creatinine
ratio
15.6.1.2.3.
Imaging
tests
15.6.1.2.4.
Kidney
biopsy.
15.6.1.2.5.
Others
15.6.1.3.
Saudi
Arabia Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
15.6.1.3.1.
Drug
Treatment
15.6.1.3.1.1. SGLT2 inhibitors
15.6.1.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.1.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.1.3.1.4. Others
15.6.1.3.2.
Dietary
Changes
15.6.1.3.3.
Dialysis
15.6.1.3.4.
Kidney
Transplant
15.6.1.4.
Saudi
Arabia Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1.
Hospitals
And Clinics
15.6.1.4.2.
Diabetes
Management Centers
15.6.1.4.3.
Research
Institutes
15.6.2. UAE
15.6.2.1.
UAE
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
15.6.2.1.1.
Type 1
15.6.2.1.2.
Type 2
15.6.2.2.
UAE
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
15.6.2.2.1.
Urinary
albumin test
15.6.2.2.2.
Albumin/creatinine
ratio
15.6.2.2.3.
Imaging
tests
15.6.2.2.4.
Kidney
biopsy.
15.6.2.2.5.
Others
15.6.2.3.
UAE
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
15.6.2.3.1.
Drug
Treatment
15.6.2.3.1.1. SGLT2 inhibitors
15.6.2.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.2.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.2.3.1.4. Others
15.6.2.3.2.
Dietary
Changes
15.6.2.3.3.
Dialysis
15.6.2.3.4.
Kidney
Transplant
15.6.2.4.
UAE Diabetic
Nephropathy Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.2.4.1.
Hospitals
And Clinics
15.6.2.4.2.
Diabetes
Management Centers
15.6.2.4.3.
Research
Institutes
15.6.3. Egypt
15.6.3.1.
Egypt
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
15.6.3.1.1.
Type 1
15.6.3.1.2.
Type 2
15.6.3.2.
Egypt
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
15.6.3.2.1.
Urinary
albumin test
15.6.3.2.2.
Albumin/creatinine
ratio
15.6.3.2.3.
Imaging
tests
15.6.3.2.4.
Kidney
biopsy.
15.6.3.2.5.
Others
15.6.3.3.
Egypt
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
15.6.3.3.1.
Drug
Treatment
15.6.3.3.1.1. SGLT2 inhibitors
15.6.3.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.3.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.3.3.1.4. Others
15.6.3.3.2.
Dietary
Changes
15.6.3.3.3.
Dialysis
15.6.3.3.4.
Kidney
Transplant
15.6.3.4.
Egypt
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.3.4.1.
Hospitals
And Clinics
15.6.3.4.2.
Diabetes
Management Centers
15.6.3.4.3.
Research
Institutes
15.6.4. Kuwait
15.6.4.1.
Kuwait
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
15.6.4.1.1.
Type 1
15.6.4.1.2.
Type 2
15.6.4.2.
Kuwait
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
15.6.4.2.1.
Urinary
albumin test
15.6.4.2.2.
Albumin/creatinine
ratio
15.6.4.2.3.
Imaging
tests
15.6.4.2.4.
Kidney
biopsy.
15.6.4.2.5.
Others
15.6.4.3.
Kuwait
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
15.6.4.3.1.
Drug
Treatment
15.6.4.3.1.1. SGLT2 inhibitors
15.6.4.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.4.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.4.3.1.4. Others
15.6.4.3.2.
Dietary
Changes
15.6.4.3.3.
Dialysis
15.6.4.3.4.
Kidney
Transplant
15.6.4.4.
Kuwait
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.4.4.1.
Hospitals
And Clinics
15.6.4.4.2.
Diabetes
Management Centers
15.6.4.4.3.
Research
Institutes
15.6.5. South Africa
15.6.5.1.
South
Africa Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diabetics Type
15.6.5.1.1.
Type 1
15.6.5.1.2.
Type 2
15.6.5.2.
South
Africa Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.5.2.1.
Urinary
albumin test
15.6.5.2.2.
Albumin/creatinine
ratio
15.6.5.2.3.
Imaging
tests
15.6.5.2.4.
Kidney
biopsy.
15.6.5.2.5.
Others
15.6.5.3.
South
Africa Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Treatment
15.6.5.3.1.
Drug
Treatment
15.6.5.3.1.1. SGLT2 inhibitors
15.6.5.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.5.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.5.3.1.4. Others
15.6.5.3.2.
Dietary
Changes
15.6.5.3.3.
Dialysis
15.6.5.3.4.
Kidney
Transplant
15.6.5.4.
South
Africa Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1.
Hospitals
And Clinics
15.6.5.4.2.
Diabetes
Management Centers
15.6.5.4.3.
Research
Institutes
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
15.6.6.1.1.
Type 1
15.6.6.1.2.
Type 2
15.6.6.2.
Rest of
Middle East & Africa Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.6.2.1.
Urinary
albumin test
15.6.6.2.2.
Albumin/creatinine
ratio
15.6.6.2.3.
Imaging
tests
15.6.6.2.4.
Kidney
biopsy.
15.6.6.2.5.
Others
15.6.6.3.
Rest of
Middle East & Africa Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Treatment
15.6.6.3.1.
Drug
Treatment
15.6.6.3.1.1. SGLT2 inhibitors
15.6.6.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
15.6.6.3.1.3. Angiotensin receptor blockers (ARBs)
15.6.6.3.1.4. Others
15.6.6.3.2.
Dietary
Changes
15.6.6.3.3.
Dialysis
15.6.6.3.4.
Kidney
Transplant
15.6.6.4.
Rest of
Middle East & Africa Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1.
Hospitals
And Clinics
15.6.6.4.2.
Diabetes
Management Centers
15.6.6.4.3.
Research
Institutes
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Diabetics Type
15.7.3. By Diagnosis
15.7.4. By Treatment
15.7.5. By End Users
16. Latin America Diabetic Nephropathy Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin America Diabetic Nephropathy Market Revenue (US$ Mn)
16.2. Latin America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diabetics Type
16.2.1. Type 1
16.2.2. Type 2
16.3. Latin America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.3.1. Urinary albumin test
16.3.2. Albumin/creatinine ratio
16.3.3. Imaging tests
16.3.4. Kidney biopsy.
16.3.5. Others
16.4. Latin America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Treatment
16.4.1. Drug Treatment
16.4.1.1.
SGLT2
inhibitors
16.4.1.2.
Angiotensin
converting enzyme (ACE) inhibitors
16.4.1.3.
Angiotensin
receptor blockers (ARBs)
16.4.1.4.
Others
16.4.2. Dietary Changes
16.4.3. Dialysis
16.4.4. Kidney Transplant
16.5. Latin America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By End
Users
16.5.1. Hospitals And Clinics
16.5.2. Diabetes Management Centers
16.5.3. Research Institutes
16.6. Latin America Diabetic Nephropathy Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1.
Brazil
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
16.6.1.1.1.
Type 1
16.6.1.1.2.
Type 2
16.6.1.2.
Brazil
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
16.6.1.2.1.
Urinary
albumin test
16.6.1.2.2.
Albumin/creatinine
ratio
16.6.1.2.3.
Imaging
tests
16.6.1.2.4.
Kidney
biopsy.
16.6.1.2.5.
Others
16.6.1.3.
Brazil
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
16.6.1.3.1.
Drug
Treatment
16.6.1.3.1.1. SGLT2 inhibitors
16.6.1.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
16.6.1.3.1.3. Angiotensin receptor blockers (ARBs)
16.6.1.3.1.4. Others
16.6.1.3.2.
Dietary
Changes
16.6.1.3.3.
Dialysis
16.6.1.3.4.
Kidney
Transplant
16.6.1.4.
Brazil
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.1.4.1.
Hospitals
And Clinics
16.6.1.4.2.
Diabetes
Management Centers
16.6.1.4.3.
Research
Institutes
16.6.2. Argentina
16.6.2.1.
Argentina
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diabetics Type
16.6.2.1.1.
Type 1
16.6.2.1.2.
Type 2
16.6.2.2.
Argentina
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Diagnosis
16.6.2.2.1.
Urinary
albumin test
16.6.2.2.2.
Albumin/creatinine
ratio
16.6.2.2.3.
Imaging
tests
16.6.2.2.4.
Kidney
biopsy.
16.6.2.2.5.
Others
16.6.2.3.
Argentina
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By Treatment
16.6.2.3.1.
Drug
Treatment
16.6.2.3.1.1. SGLT2 inhibitors
16.6.2.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
16.6.2.3.1.3. Angiotensin receptor blockers (ARBs)
16.6.2.3.1.4. Others
16.6.2.3.2.
Dietary
Changes
16.6.2.3.3.
Dialysis
16.6.2.3.4.
Kidney
Transplant
16.6.2.4.
Argentina
Diabetic Nephropathy Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.2.4.1.
Hospitals
And Clinics
16.6.2.4.2.
Diabetes
Management Centers
16.6.2.4.3.
Research
Institutes
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Diabetics Type
16.6.3.1.1.
Type 1
16.6.3.1.2.
Type 2
16.6.3.2.
Rest of
Latin America Diabetic Nephropathy Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
16.6.3.2.1.
Urinary
albumin test
16.6.3.2.2.
Albumin/creatinine
ratio
16.6.3.2.3.
Imaging
tests
16.6.3.2.4.
Kidney
biopsy.
16.6.3.2.5.
Others
16.6.3.3.
Rest of
Latin America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By Treatment
16.6.3.3.1.
Drug
Treatment
16.6.3.3.1.1. SGLT2 inhibitors
16.6.3.3.1.2. Angiotensin converting enzyme (ACE)
inhibitors
16.6.3.3.1.3. Angiotensin receptor blockers (ARBs)
16.6.3.3.1.4. Others
16.6.3.3.2.
Dietary
Changes
16.6.3.3.3.
Dialysis
16.6.3.3.4.
Kidney
Transplant
16.6.3.4.
Rest of
Latin America Diabetic Nephropathy
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1.
Hospitals
And Clinics
16.6.3.4.2.
Diabetes
Management Centers
16.6.3.4.3.
Research
Institutes
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Diabetics Type
16.7.3. By Diagnosis
16.7.4. By Treatment
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. AbbVie Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. AstraZeneca
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Bayer AG
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. ChemoCentryx, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Genkyotex
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Goldfinch Bio, Inc.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Janssen Pharmaceutical Companies (Johnson
& Johnson.)
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Mesoblast Ltd
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Mitsubishi Tanabe Pharma Corporation
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Novartis AG
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Other Industry Participants
19. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
